Question 1

My ADHD patient's anxiety got worse on stimulants - is it the medication or a comorbidity?

Accepted Answer

The highest-quality meta-analysis (Coughlin et al., 2015; PMID 26402485; 23 RCTs, 2,959 children) shows stimulants REDUCE overall anxiety risk (RR 0.86, p=0.004) in ADHD populations — higher doses associated with lower anxiety risk. 'Worsened anxiety' on stimulants is usually somatic mimicry: stimulant-induced tachycardia and jitteriness misinterpreted as panic by an anxious child. The MTA moderator data (Jensen et al., 2001; PMID 11211363) found that anxious ADHD children without ODD respond uniquely well to behavioral therapy alone — the only subgroup where this matched medication efficacy. CAMS subsample data (Halldorsdottir et al., 2015; PMID 25310142) show that untreated ADHD specifically predicts reduced CBT response for anxiety. Treatment sequencing: treat whichever disorder is most functionally impairing first. Consider atomoxetine when both conditions are severe (Cortese et al., 2018, Lancet Psychiatry; PMID 30097390).

Question 2

How common is stimulant-induced anxiety?

Accepted Answer

The highest-quality meta-analysis (Coughlin et al., 2015; PMID 26402485; 23 RCTs, 2,959 children) shows stimulants REDUCE overall anxiety risk (RR 0.86, p=0.004) in ADHD populations — higher doses associated with lower anxiety risk. 'Worsened anxiety' on stimulants is usually somatic mimicry: stimulant-induced tachycardia and jitteriness misinterpreted as panic by an anxious child. The MTA moderator data (Jensen et al., 2001; PMID 11211363) found that anxious ADHD children without ODD respond uniquely well to behavioral therapy alone — the only subgroup where this matched medication efficacy. CAMS subsample data (Halldorsdottir et al., 2015; PMID 25310142) show that untreated ADHD specifically predicts reduced CBT response for anxiety. Treatment sequencing: treat whichever disorder is most functionally impairing first. Consider atomoxetine when both conditions are severe (Cortese et al., 2018, Lancet Psychiatry; PMID 30097390).

Question 3

How do I tell pre-existing comorbid anxiety from iatrogenic stimulant anxiety?

Accepted Answer

The highest-quality meta-analysis (Coughlin et al., 2015; PMID 26402485; 23 RCTs, 2,959 children) shows stimulants REDUCE overall anxiety risk (RR 0.86, p=0.004) in ADHD populations — higher doses associated with lower anxiety risk. 'Worsened anxiety' on stimulants is usually somatic mimicry: stimulant-induced tachycardia and jitteriness misinterpreted as panic by an anxious child. The MTA moderator data (Jensen et al., 2001; PMID 11211363) found that anxious ADHD children without ODD respond uniquely well to behavioral therapy alone — the only subgroup where this matched medication efficacy. CAMS subsample data (Halldorsdottir et al., 2015; PMID 25310142) show that untreated ADHD specifically predicts reduced CBT response for anxiety. Treatment sequencing: treat whichever disorder is most functionally impairing first. Consider atomoxetine when both conditions are severe (Cortese et al., 2018, Lancet Psychiatry; PMID 30097390).

Question 4

Should I reduce the stimulant dose, switch to atomoxetine, or add an anxiolytic?

Accepted Answer

The highest-quality meta-analysis (Coughlin et al., 2015; PMID 26402485; 23 RCTs, 2,959 children) shows stimulants REDUCE overall anxiety risk (RR 0.86, p=0.004) in ADHD populations — higher doses associated with lower anxiety risk. 'Worsened anxiety' on stimulants is usually somatic mimicry: stimulant-induced tachycardia and jitteriness misinterpreted as panic by an anxious child. The MTA moderator data (Jensen et al., 2001; PMID 11211363) found that anxious ADHD children without ODD respond uniquely well to behavioral therapy alone — the only subgroup where this matched medication efficacy. CAMS subsample data (Halldorsdottir et al., 2015; PMID 25310142) show that untreated ADHD specifically predicts reduced CBT response for anxiety. Treatment sequencing: treat whichever disorder is most functionally impairing first. Consider atomoxetine when both conditions are severe (Cortese et al., 2018, Lancet Psychiatry; PMID 30097390).

Question 5

Can guanfacine treat both ADHD and anxiety simultaneously?

Accepted Answer

The highest-quality meta-analysis (Coughlin et al., 2015; PMID 26402485; 23 RCTs, 2,959 children) shows stimulants REDUCE overall anxiety risk (RR 0.86, p=0.004) in ADHD populations — higher doses associated with lower anxiety risk. 'Worsened anxiety' on stimulants is usually somatic mimicry: stimulant-induced tachycardia and jitteriness misinterpreted as panic by an anxious child. The MTA moderator data (Jensen et al., 2001; PMID 11211363) found that anxious ADHD children without ODD respond uniquely well to behavioral therapy alone — the only subgroup where this matched medication efficacy. CAMS subsample data (Halldorsdottir et al., 2015; PMID 25310142) show that untreated ADHD specifically predicts reduced CBT response for anxiety. Treatment sequencing: treat whichever disorder is most functionally impairing first. Consider atomoxetine when both conditions are severe (Cortese et al., 2018, Lancet Psychiatry; PMID 30097390).

PsychHQ

ADHD-Anxiety Comorbidity: Stimulant Safety, MTA Moderators, and Treatment Sequencing